Your browser doesn't support javascript.
loading
Clinical and molecular characterization of HER2 amplified-pancreatic cancer.
Chou, Angela; Waddell, Nicola; Cowley, Mark J; Gill, Anthony J; Chang, David K; Patch, Ann-Marie; Nones, Katia; Wu, Jianmin; Pinese, Mark; Johns, Amber L; Miller, David K; Kassahn, Karin S; Nagrial, Adnan M; Wasan, Harpreet; Goldstein, David; Toon, Christopher W; Chin, Venessa; Chantrill, Lorraine; Humphris, Jeremy; Mead, R Scott; Rooman, Ilse; Samra, Jaswinder S; Pajic, Marina; Musgrove, Elizabeth A; Pearson, John V; Morey, Adrienne L; Grimmond, Sean M; Biankin, Andrew V.
Afiliación
  • Chou A; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Waddell N; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Cowley MJ; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Gill AJ; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Department of Anatomical Pathology, Royal North Shore Hospital, St Lenoards, Sydney, Australia ; Sydney Medical School, University of Sydney, Sydney, Australia.
  • Chang DK; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK ; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • Patch AM; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Nones K; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Wu J; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Pinese M; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Johns AL; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
  • Miller DK; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Kassahn KS; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Nagrial AM; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Wasan H; Department of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Goldstein D; Prince of Wales Clinical School, University of New South Wales and Prince of Wales Hospital, Sydney, Australia.
  • Toon CW; Department of Anatomical Pathology, Royal North Shore Hospital, St Lenoards, Sydney, Australia ; Sydney Medical School, University of Sydney, Sydney, Australia ; Histopath Pathology, 97 Waterloo Road, North Ryde, NSW 2113, Australia.
  • Chin V; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Chantrill L; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia ; Macarthur Cancer Therapy Centre, Sydney South West District Health Service, Sydney, NSW, Australia.
  • Humphris J; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
  • Mead RS; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Rooman I; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Samra JS; Upper Gastrointestinal Surgery Unit, Royal North Shore Hospital, Sydney, Australia.
  • Pajic M; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Musgrove EA; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Pearson JV; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
  • Morey AL; Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia.
  • Grimmond SM; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Biankin AV; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK ; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
Genome Med ; 5(8): 78, 2013.
Article en En | MEDLINE | ID: mdl-24004612
BACKGROUND: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized to exploit the potential of anti-HER2 therapies. METHODS: HER2 amplification was detected and further analyzed using multiple genomic sequencing approaches. Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC). RESULTS: An amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified cancers in the USA is >22,000 per annum. CONCLUSIONS: HER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Genome Med Año: 2013 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Genome Med Año: 2013 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido